Administration of ruxolitinib had no effect on tumor growth kinetics (Supplemental Figure 3A), but it significantly suppressed fat loss (Supplemental Figure 3B) and adipose STAT3 phosphorylation (Supplemental Figure 3C) induced in the context of STK11-variant H1573 tumors. This evidence concerns the gene STK11 and neoplasm.